{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.29","value":"1.1"},{"groupId":"OG001","spread":"13.78","value":"-0.4"}]}],"title":"Urinary symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.41","value":"1.0"},{"groupId":"OG001","spread":"19.80","value":"0.0"}]}],"title":"Incontinence aid use"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.92","value":"1.2"},{"groupId":"OG001","spread":"9.51","value":"2.0"}]}],"title":"Bowel symptoms"}],"denoms":[{"counts":[{"groupId":"OG000","value":"537"},{"groupId":"OG001","value":"256"}],"units":"Participants"}],"description":"Subscale assessments of urinary symptoms (9 items) and bowel symptoms (4 items) from the EORTC-QLQ-PR25 25-item prostate cancer module of the EORTC are presented. Questions used 4 point scale (1 'Not at all' to 4 'Very much'). All raw domain scores are linearly transformed to a 0-100 scale. A decrease in symptom scores indicates improvement (lower level of symptoms/problems).","dispersionType":"Standard Deviation","groups":[{"description":"Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1.","id":"OG000","title":"Relugolix"},{"description":"Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan and Taiwan), every 3 months by subcutaneous injection.","id":"OG001","title":"Leuprolide Acetate"}],"paramType":"MEAN","populationDescription":"All randomized participants who received at least 1 dose of study drug and had analyzable data at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 49 Day 1 (Day 337)","title":"Change From Baseline In QoL Total Score For Urinary And Bowel Symptoms Domains As Assessed By The EORTC-QLQ-PR25","type":"SECONDARY","unitOfMeasure":"score on a scale"}